Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue ... Aerie Pharmaceuticals (AERI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.73 per share a year ago. NASDAQ:AERI | Analyst Ratings

AERI stock: Aerie Pharmaceuticals Inc - Super Stock Screener Aerie Pharmaceuticals Inc's stock rating is based on fundamental analysis. Don't miss AERI stock next rating changes Join Now | Login. Need Help? Call 1­-866-­796-­7386 Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical. AERI - Aerie Pharmaceuticals Stock Price - Barchart.com 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. AERI Stock Price, Forecast & News (Aerie Pharmaceuticals) Analyzing Aerie Pharmaceuticals (NASDAQ:AERI) stock? View AERI's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock …

Aerie Pharmaceuticals Stock Jumps on FDA Drug Approval

Nov 27, 2019 · Not to mention each has received enough bullish recommendations in the last three months to earn a “strong buy” consensus rating. See the AERI stock analysis. Cytokinetics (CYTK) The 9 Best Biotech Stocks to Buy for a Blowout 2019 Yang’s first biotech stock pick for 2019 is Aerie Pharmaceuticals (AERI, $46.50), an ocular-focused company that has developed two groundbreaking glaucoma drugs: Rhopressa (launched in 2018) and Analyst Reviews Aerie Pharmaceuticals Inc (AERI) in Light ...

View the latest stock recommendations for Aerie Pharmaceuticals, Inc. (AERI) by investors and analysts. Find out the buy/sell mix, consensus price and top investors' opinion on Aerie Pharmaceuticals, …

Nov 06, 2018 · A erie Pharmaceuticals (AERI) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to … AERI Stock Quote - Aerie Pharmaceuticals Inc. AERI stock quote information – including stock price, key financials, stock charts and investing ideas containing AERI. What We Offer. Individual Investors. recommendations, advice, investment ideas or other materials generated within Motif's Network by customers and users participating with Social Groups. The content within the Motif Analyst Information for Aerie Pharmaceuticals Inc.

AERI Archives - TipRanks Financial Blog

Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue ... Aerie Pharmaceuticals (AERI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.73 per share a year ago. NASDAQ:AERI | Analyst Ratings Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $40.00. The company’s shares closed last Monday at $13.50, close to its 52-week low of $10.80. Aerie Pharmaceuticals financial analysis 2020 | AERI ... The modest gains experienced by current holders of Aerie Pharmaceuticals could raise concerns from investors as the firm closed today at a share price of 20.73 on 443374.000 in volume. The company executives have been quite successful with maneuvering the stock at opportune times to take advantage of all market conditions in January.The stock standard deviation of daily returns for 30 days

Get Aerie Pharmaceuticals Inc (AERI:NASDAQ) real-time stock quotes, news and financial information from CNBC.

Meet the eye care VISIONaerieS™ building the next major ophthalmic pharmaceutical company. MORE. Stock Information. NASDAQ: AERI. $14.01. Mar 17 

Investors Catching Stocks Watsco, Inc.(NYSE:WSO): Aerie ... Mar 12, 2020 · The Stock currently has a Weekly Volatility of 8.47% and Monthly Volatility of 4.01%. Aerie Pharmaceuticals, Inc. (AERI) will report its next earnings on Feb 20 AMC. Aerie Pharmaceuticals (NASDAQ:AERI) Cut to “Hold” at Zacks ... Zacks Investment Research cut shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a buy rating to a hold rating in a research note published on Monday morning, Zacks.com reports. The brokerage Aerie Pharmaceuticals Stock Jumps on FDA Drug Approval Mar 13, 2019 · Drug stock Aerie Pharmaceuticals is one of the best stocks out of the gates today thanks to an FDA approval Options Recommendations Aerie … Investors have great interest in Newmark Group Inc. (NMRK ...